Use of a Multigene Prognostic Assay for Selection of Adjuvant Chemotherapy in Patients With Stage II Colon Cancer: Impact on Quality-Adjusted Life Expectancy and Costs.
Journal of Clinical Oncology - United States
doi 10.1200/jco.2011.29.4_suppl.491
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2011
Authors
Publisher
American Society of Clinical Oncology (ASCO)